India's healthcare sector is poised for stronger growth over the next three years, driven by new drug launches and GLP-1 medications entering the domestic market. According to Systematix Research, branded formulation growth is expected to accelerate in the high single-digit range, supporting pharmaceutical companies with strong domestic presence. However, the US generics business faces headwinds, with earnings projected to remain flat for most players due to ongoing competitive pressures. Biosimilar launches present new opportunities in the US market, though profitability gains remain uncertain. Companies investing strategically in biosimilars with less crowded pipelines and maintaining robust balance sheets are better positioned for resilience and growth in this evolving landscape.
